HUP0303826A2 - Eljárások bőr rendellenességeinek kezelésére vagy prevenciójára CD2-kötőágensek alkalmazásával - Google Patents
Eljárások bőr rendellenességeinek kezelésére vagy prevenciójára CD2-kötőágensek alkalmazásávalInfo
- Publication number
- HUP0303826A2 HUP0303826A2 HU0303826A HUP0303826A HUP0303826A2 HU P0303826 A2 HUP0303826 A2 HU P0303826A2 HU 0303826 A HU0303826 A HU 0303826A HU P0303826 A HUP0303826 A HU P0303826A HU P0303826 A2 HUP0303826 A2 HU P0303826A2
- Authority
- HU
- Hungary
- Prior art keywords
- treating
- methods
- binding agents
- skin disorders
- preventing skin
- Prior art date
Links
- 239000011230 binding agent Substances 0.000 title abstract 2
- 208000017520 skin disease Diseases 0.000 title 1
- 108010084313 CD58 Antigens Proteins 0.000 abstract 2
- 201000004681 Psoriasis Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002500 effect on skin Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2824—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD58
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
(57) A találmány tárgyát képezi CD2-kötőágens, például CD2/LFA-3-kölcsönhatás inhibitorának (például LFA-3/IgG fúziós polipeptid)alkalmazása kiegészítő ágenssel, például UVB-besugárzássalkombinációban gyulladásos vagy autoimmun rendellenesség, példáulpszoriázis (pikkelysömör), atópiás dermatitisz vagy más olyanepidermális vagy dermális rendellenességek kezelésére, amelyeketabnormális T-sejt-aktivitás vagy proliferáció jellemez. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26596401P | 2001-02-01 | 2001-02-01 | |
PCT/US2002/002314 WO2002060480A1 (en) | 2001-02-01 | 2002-01-25 | Methods for treating or preventing skin disorders using cd2-binding agents |
Publications (1)
Publication Number | Publication Date |
---|---|
HUP0303826A2 true HUP0303826A2 (hu) | 2004-03-01 |
Family
ID=23012611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0303826A HUP0303826A2 (hu) | 2001-02-01 | 2002-01-25 | Eljárások bőr rendellenességeinek kezelésére vagy prevenciójára CD2-kötőágensek alkalmazásával |
Country Status (22)
Country | Link |
---|---|
US (3) | US20040170635A1 (hu) |
EP (1) | EP1409015A4 (hu) |
JP (1) | JP2004527477A (hu) |
KR (1) | KR20040043112A (hu) |
CN (1) | CN1527723A (hu) |
AR (1) | AR035079A1 (hu) |
BG (1) | BG108020A (hu) |
BR (1) | BR0206905A (hu) |
CA (1) | CA2436411A1 (hu) |
CZ (1) | CZ20032081A3 (hu) |
EA (1) | EA200300849A1 (hu) |
EE (1) | EE200300366A (hu) |
GE (1) | GEP20063828B (hu) |
HU (1) | HUP0303826A2 (hu) |
IS (1) | IS6894A (hu) |
MX (1) | MXPA03006919A (hu) |
NO (1) | NO20033443L (hu) |
PL (1) | PL368556A1 (hu) |
SK (1) | SK9722003A3 (hu) |
WO (1) | WO2002060480A1 (hu) |
YU (1) | YU61203A (hu) |
ZA (1) | ZA200305936B (hu) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6764681B2 (en) | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
ES2252999T3 (es) * | 1998-08-31 | 2006-05-16 | Biogen Idec Ma Inc. | Modulacion de celulas t efectoras y de memoria con un ligando de cd2. |
WO2002098370A2 (en) * | 2001-03-02 | 2002-12-12 | Medimmune, Inc. | Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders |
AU2002320352A1 (en) | 2001-07-24 | 2003-02-17 | Biogen Idec Ma Inc. | Methods for treating or preventing sclerotic disorders using cd2-binding agents |
DE60326370D1 (de) | 2002-08-12 | 2009-04-09 | Actavis Group Hf | Verwendung von cgrp-antagonisten-verbindungen zur behandlung von psoriasis |
US11517612B2 (en) | 2016-11-18 | 2022-12-06 | Nepsone Ehf | Methods of treating inflammatory skin disorders |
GB0307864D0 (en) * | 2003-04-04 | 2003-05-14 | Novartis Ag | Pharmaceutical composition |
MXPA06008918A (es) * | 2004-02-06 | 2007-03-07 | Astellas Llc | Metodos de tratamiento de trastornos de la piel. |
US20080020383A1 (en) * | 2004-05-04 | 2008-01-24 | Genaissance Pharmaceuticals, Inc. | Haplotype Markers And Methods Of Using The Same To Determine Response To Treatment |
EP1750747A1 (en) * | 2004-05-07 | 2007-02-14 | Astellas US LLC | Soluble lfa-3 polypeptide for treating viral disorders |
US20060078580A1 (en) * | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
CN101113459A (zh) * | 2007-07-16 | 2008-01-30 | 东莞太力生物工程有限公司 | 一种重组复制缺陷型病毒、含有该病毒的药物组合物及其应用 |
US9289469B2 (en) | 2009-09-10 | 2016-03-22 | Mayo Foundation For Medical Education And Research | Depleting immunosuppressive monocytes within a mammal |
US9266957B2 (en) | 2009-11-10 | 2016-02-23 | Mayo Foundation For Medical Education And Research | Methods and materials for treating renal cell carcinoma and glioblastoma multiforme |
WO2014025198A2 (ko) * | 2012-08-09 | 2014-02-13 | 주식회사 한독 | Lfa3 변이체 및 상기 변이체 또는 lfa3 cd2 결합영역과 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도 |
WO2014078272A1 (en) | 2012-11-13 | 2014-05-22 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing immune system profiles |
WO2014182761A1 (en) | 2013-05-09 | 2014-11-13 | Mayo Foundation For Medical Education And Research | Treating patients based on immune subtypes |
WO2023224980A1 (en) * | 2022-05-17 | 2023-11-23 | The Uab Research Foundation | Methods and compositions for treating or preventing inflammatory skin disorders |
WO2024050455A2 (en) * | 2022-08-31 | 2024-03-07 | Heitmeyer Jamie Nicole | Anti-rhd antibodies for treating inflammatory dermal condition |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6764681B2 (en) * | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
ES2112335T3 (es) * | 1991-10-07 | 1998-04-01 | Biogen Inc | Procedimiento profilactico o terapeutico de enfermedades de la piel causadas por celulas que presentan antigenos por medio de inhibidores de la interaccion entre cd2 y lfa-3. |
US6162432A (en) * | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
US5817311A (en) * | 1993-03-05 | 1998-10-06 | Universite Catholique De Louvain | Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies |
US5730979A (en) * | 1993-03-05 | 1998-03-24 | Universite Catholique Delouvain | LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation |
US5951983A (en) * | 1993-03-05 | 1999-09-14 | Universite Catholique De Louvain | Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies |
ES2252999T3 (es) * | 1998-08-31 | 2006-05-16 | Biogen Idec Ma Inc. | Modulacion de celulas t efectoras y de memoria con un ligando de cd2. |
-
2002
- 2002-01-25 WO PCT/US2002/002314 patent/WO2002060480A1/en not_active Application Discontinuation
- 2002-01-25 CZ CZ20032081A patent/CZ20032081A3/cs unknown
- 2002-01-25 BR BR0206905-9A patent/BR0206905A/pt not_active Application Discontinuation
- 2002-01-25 HU HU0303826A patent/HUP0303826A2/hu unknown
- 2002-01-25 PL PL02368556A patent/PL368556A1/xx not_active Application Discontinuation
- 2002-01-25 EE EEP200300366A patent/EE200300366A/xx unknown
- 2002-01-25 JP JP2002560671A patent/JP2004527477A/ja not_active Withdrawn
- 2002-01-25 CA CA002436411A patent/CA2436411A1/en not_active Abandoned
- 2002-01-25 US US10/470,764 patent/US20040170635A1/en not_active Abandoned
- 2002-01-25 EA EA200300849A patent/EA200300849A1/ru unknown
- 2002-01-25 EP EP02704253A patent/EP1409015A4/en not_active Withdrawn
- 2002-01-25 MX MXPA03006919A patent/MXPA03006919A/es unknown
- 2002-01-25 KR KR10-2003-7010218A patent/KR20040043112A/ko not_active Application Discontinuation
- 2002-01-25 CN CNA028079191A patent/CN1527723A/zh active Pending
- 2002-01-25 YU YU61203A patent/YU61203A/sh unknown
- 2002-01-25 GE GE5273A patent/GEP20063828B/en unknown
- 2002-01-25 SK SK972-2003A patent/SK9722003A3/sk unknown
- 2002-01-28 AR ARP020100293A patent/AR035079A1/es unknown
- 2002-12-26 US US10/329,599 patent/US20030185824A1/en not_active Abandoned
-
2003
- 2003-07-22 BG BG108020A patent/BG108020A/bg unknown
- 2003-07-25 IS IS6894A patent/IS6894A/is unknown
- 2003-07-31 ZA ZA2003/05936A patent/ZA200305936B/en unknown
- 2003-08-01 NO NO20033443A patent/NO20033443L/no unknown
-
2005
- 2005-12-20 US US11/312,627 patent/US20070031443A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20040170635A1 (en) | 2004-09-02 |
CN1527723A (zh) | 2004-09-08 |
CA2436411A1 (en) | 2002-08-08 |
JP2004527477A (ja) | 2004-09-09 |
IS6894A (is) | 2003-07-25 |
EP1409015A1 (en) | 2004-04-21 |
YU61203A (sh) | 2006-05-25 |
PL368556A1 (en) | 2005-04-04 |
NO20033443D0 (no) | 2003-08-01 |
BG108020A (bg) | 2004-03-31 |
GEP20063828B (en) | 2006-05-10 |
MXPA03006919A (es) | 2004-06-02 |
WO2002060480A1 (en) | 2002-08-08 |
EP1409015A4 (en) | 2006-04-12 |
BR0206905A (pt) | 2004-07-06 |
US20030185824A1 (en) | 2003-10-02 |
NO20033443L (no) | 2003-09-30 |
ZA200305936B (en) | 2005-01-26 |
US20070031443A1 (en) | 2007-02-08 |
CZ20032081A3 (cs) | 2004-01-14 |
SK9722003A3 (en) | 2004-05-04 |
AR035079A1 (es) | 2004-04-14 |
WO2002060480A9 (en) | 2004-05-27 |
KR20040043112A (ko) | 2004-05-22 |
EA200300849A1 (ru) | 2004-02-26 |
EE200300366A (et) | 2003-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0303826A2 (hu) | Eljárások bőr rendellenességeinek kezelésére vagy prevenciójára CD2-kötőágensek alkalmazásával | |
EP1832598A3 (en) | Therapeutic treatment of androgen receptor driven conditions | |
DE69834827D1 (en) | Phototherapeutische systeme | |
AU2209800A (en) | Method of using a matrix metalloproteinase inhibitor and radiation therapy as combination therapy in the treatment of neoplasia | |
ATE493131T1 (de) | Chinazolin-4-one als inhibitoren der humanen phosphatidylinositol-3-kinase delta | |
EA200200990A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы дельта человека | |
EP1648385A4 (en) | SYSTEM AND METHOD FOR THE PHOTODYNAMIC TREATMENT OF COMBUSTIONS, WOUNDS AND RELATED SKIN DISEASES | |
DK0723444T3 (da) | Levobupivacain, som er egnet til behandling af kronisk smerte | |
WO2003100574A3 (en) | Dental appliances and systems and methods for distributing dental appliances | |
BG101126A (en) | The use of muramylpeptide compounds | |
YU89103A (sh) | Novi postupak lečenja opsesivno-kompulsivnog poremećaja (okp) i poremećaja povezanih sa okp-om, korišćenjem gvg-a | |
DE60037032D1 (de) | Anwendung von pdt zur inhibierung von hyperplasie der intima | |
AU6314296A (en) | Therapeutic agents and autoimmune diseases | |
DE60214207D1 (de) | Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis | |
IL189190A0 (en) | Use of fluorinated triazoles for treating pain and affective or attention disorders | |
UA28400A (uk) | Спосіб лікування мікробної екземи | |
WO2001089489A3 (de) | Transdermale applikation von wirkstoffen direkt über der halsschlagader | |
UA49674A (uk) | Спосіб комплексного лікування генералізованих форм злоякісної меланоми шкіри | |
UA8280A (uk) | Спосіб лікування псоріазу |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |